Published in AIDS Weekly, July 31st, 2000
The phenotypic test used in the study (Antivirogram) is the only one to have been proven against all the subtypes of HIV, which predominate in developing countries in Africa and elsewhere.
The test was chosen to profile drugs from a second generation of non-nucleoside reverse transcriptase inhibitors (NNRTIs), being developed by DuPont Pharmaceuticals. First generation NNRTIs...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of AIDS Weekly
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.